What have we learned from gene expression profiles in Huntington's disease?

被引:109
|
作者
Seredenina, Tamara [1 ]
Luthi-Carter, Ruth [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Lab Funct Neurogen, CH-1015 Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
Polyglutamine disease; huntingtin; Transcriptomic profiling; Striatum; Cortex; Muscle; Blood; Microarray; Biomarker; HISTONE DEACETYLASE INHIBITORS; NEURONAL INTRANUCLEAR INCLUSIONS; CRE-MEDIATED TRANSCRIPTION; ADENOSINE A(2A) RECEPTORS; TRANSGENIC MOUSE MODELS; CELL-CELL INTERACTIONS; MUTANT-HUNTINGTIN; SYNAPTIC PLASTICITY; BINDING-PROTEIN; MESSENGER-RNA;
D O I
10.1016/j.nbd.2011.07.001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The availability of many high-quality genome-wide expression datasets has provided an exciting and unique opportunity to better understand the molecular etiology of Huntington's disease. Combining this knowledge with other aspects of huntingtin biology and disease modification screens is yielding important new insights into disease-mitigating therapeutic strategies. Having followed this line of inquiry for some time, we note that there have been a number of surprises regarding the subsequently confirmed relationships between gene expression and disease etiology. Moreover, the complexity and sheer number of proposed mechanisms by which huntingtin can perturb gene expression continues to expand. Nonetheless, ongoing efforts to enthusiastically and critically evaluate the relationships between HD pathobiology and gene expression promise to deliver accurate predictions as to which therapeutic strategies will be most effective. An exciting new arm of this research also demonstrates the power of pharmacogenomics to detect (and rule out) important neuroprotective gene expression effects. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:83 / 98
页数:16
相关论文
共 50 条
  • [21] What Have We Learned from Helioseismology, What Have We Really Learned, and What Do We Aspire to Learn?
    Gough, Douglas
    SOLAR PHYSICS, 2013, 287 (1-2) : 9 - 41
  • [22] What Have We Learned from Helioseismology, What Have We Really Learned, and What Do We Aspire to Learn?
    Douglas Gough
    Solar Physics, 2013, 287 : 9 - 41
  • [23] New therapies in Alzheimer's disease - What have we learned?
    Dodel, R.
    IMMUNOLOGY, 2011, 135 : 24 - 24
  • [24] Levodopa for Parkinson's disease.: What have we learned?
    Juri C, Carlos
    Chana C, Pedro
    REVISTA MEDICA DE CHILE, 2006, 134 (07) : 893 - 901
  • [25] Molecular genetics of Alzheimer's disease: what have we learned?
    Van Gassen, G
    Van Broeckhoven, C
    ACTA NEUROLOGICA BELGICA, 2000, 100 (02) : 65 - 76
  • [26] ALZHEIMER'S DISEASE: WHAT HAVE WE LEARNED AND WHERE MUST WE GO?
    Morris, John C.
    NEUROBIOLOGY OF AGING, 2012, 33 : S23 - S23
  • [27] Epigenetic and gene expression changes in the adolescent brain: What have we learned from animal models?
    Mychasiuk, Richelle
    Metz, Gerlinde A. S.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2016, 70 : 189 - 197
  • [28] DNA polymerase γ and disease: what we have learned from yeast
    Lodi, Tiziana
    Dallabona, Cristina
    Nolli, Cecilia
    Goffrini, Paola
    Donnini, Claudia
    Baruffini, Enrico
    FRONTIERS IN GENETICS, 2015, 6
  • [29] Therapeutic strategies in Parkinson's disease: what we have learned from animal models
    Valadas, Jorge S.
    Vos, Melissa
    Verstreken, Patrik
    YEAR IN NEUROLOGY AND PSYCHIATRY, 2015, 1338 : 16 - 37
  • [30] Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?
    Van Dam, Debby
    Vermeiren, Yannick
    Dekker, Alain D.
    Naude, Petrus J. W.
    De Deyn, Peter P.
    CURRENT ALZHEIMER RESEARCH, 2016, 13 (10) : 1145 - 1164